High risk of infection in ‘real‐world’ patients receiving ibrutinib, idelalisib or venetoclax for mature B‐cell leukaemia/lymphoma
European Journal of Haematology · 2023
DOI: 10.1111/ejh.13928 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Amanda Tey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Monash Health, Clayton, Victoria, Australia. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Monash Health, National Health and Medical Research Council, Society of Hospital Pharmacists of Australia.
Abstract (Originalsprache)
Objective
The infection risk in patients receiving ibrutinib, idelalisib or venetoclax for chronic lymphocytic leukaemia (CLL) or B‐cell lymphoma treated outside of clinical trials is incompletely defined. We sought to identify the severe infection rate and associated risk factors in a ‘real‐world’ cohort.
Methods
We conducted a retrospective cohort study of adult patients with CLL or lymphoma treated with ibrutinib, idelalisib or venetoclax.
Results
Of 67 patients identified (ibrutinib n = 53, idelalisib n = 8 and venetoclax n = 6), 32 (48%) experienced severe infection. Severe infection occurred at a rate of 65 infections per 100 person‐years, with a median of 17.8 months of therapy. Median time to first infection (IQR) was 5.4 months (1.4–15.9). Poor baseline Eastern Cooperative Oncology Group (ECOG) performance status and high Charlson Comorbidity Index (CCI) score associated with increased risk of severe infection [hazard ratios (95% CI) 1.57 (1.07–2.31, p = .018) and 1.3 (1.05–1.62, p = .016) respectively].
Conclusion
The severe infection rate for patients receiving ibrutinib, idelalisib or venetoclax for lymphoma and CLL exceeded those reported in clinical trials. Patients with poor ECOG or high CCI should be closely monitored for early signs of infection and prevention strategies actively pursued. Further prospective research is required to define optimal antimicrobial prophylaxis recommendations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Monash Health, Clayton, Victoria, Australia.
- Monash Infectious Diseases, Monash Health, Clayton, Victoria, Australia.
- Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia.
- Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
- Monash Haematology, Monash Health, Clayton, Victoria, Australia.
ORCID-Profile: Amanda Tey, James Schwarer, Robert Raffa, Emily Shi, Eldho Paul, Stephen Opat, Claire Dendle, Jake Shortt
Förderung
- Monash Health
- National Health and Medical Research Council
- Society of Hospital Pharmacists of Australia
Zitieren
APA
Tey, A., Schwarer, J., Raffa, R., Shi, E., Paul, E., Opat, S., Dendle, C., & Shortt, J. (2023). High risk of infection in ‘real‐world’ patients receiving ibrutinib, idelalisib or venetoclax for mature B‐cell leukaemia/lymphoma. European Journal of Haematology. https://doi.org/10.1111/ejh.13928
Vancouver
Tey A, Schwarer J, Raffa R, Shi E, Paul E, Opat S, et al. High risk of infection in ‘real‐world’ patients receiving ibrutinib, idelalisib or venetoclax for mature B‐cell leukaemia/lymphoma. European Journal of Haematology. 2023. doi:10.1111/ejh.13928
BibTeX
@article{Tey2023,
author = {Tey, Amanda and Schwarer, James and Raffa, Robert and Shi, Emily and Paul, Eldho and Opat, Stephen and Dendle, Claire and Shortt, Jake},
title = {High risk of infection in ‘real‐world’ patients receiving ibrutinib, idelalisib or venetoclax for mature B‐cell leukaemia/lymphoma},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.13928}
}
EUVIMED